Navigation Links
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
Date:11/8/2012

cosmetic issues noted by FDA with the product that required a reformulation effort by BDSI.  Such reformulation work has been completed and these results were submitted in October along with a formal meeting request to FDA.  In this meeting, which has been granted for mid-December, we plan to review this material with FDA and determine next steps.

Anticipated 2012/13 Milestones

BDSI is focusing its resources on achievement of the following key milestones:

  • Submission of BNX NDA for opioid dependence.  Based on the positive outcome of its pivotal PK study, BDSI anticipates it will submit an NDA to the FDA for BNX during the latter part of the second quarter of 2013.
  • Recruitment of two Phase 3 studies for BEMA Buprenorphine.  BDSI and Endo expect to continue recruitment in two Phase 3 efficacy studies for BEMA Buprenorphine for chronic pain, one in opioid experienced and one in opioid naive patient groups. The opioid experienced trial is expected to be completed with data read out before the end of 2013 and the opioid naive trial by early 2014.
  • BNX Commercialization Opportunities.  BDSI will continue its exploration of commercialization opportunities for BNX, which include ongoing licensing discussions both in the U.S. and abroad.
  • Re-launch of ONSOLIS in the U.S.  This will be dependent upon FDA's review of the new data submitted to them recently on the reformulation and the outcome of the mid-December meeting with them.
  • Exploration of Potential New Products and Technologies.  In addition to supporting its marketed product and advancing its lead products in development, BDSI is also, as in the past, exploring the application of its BEMA drug delivery technology to additional pharmaceuticals.  Furthermore, BDSI has been investigating potential new products or technologies to complement and div
    '/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
2. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... Target Patients for ALIMTA(R), (pemetrexed for injection) ... Cancer, BARCELONA, Spain, Sept. 25 ... lung cancer (NSCLC) that,are classified as having ... when treated in the second-line setting with,ALIMTA(R) ...
... Mich. Sept. 24 Velcura Therapeutics, Inc., a,biotechnology ... the,U.S. Food and Drug Administration (FDA) Sept. 20 ... VEL-0230, a drug developed to treat bone,disease. The ... was to obtain feedback from the FDA,s Division ...
Cached Medicine Technology:Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 2Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 3Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 4Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 5Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 6Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 7Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 8Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 2Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 3
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... The top executive search firm in the healthcare industry, ... healthcare executives into organizations. , Johnson Memorial Hospital ... to the residents of Johnson County and the surrounding ...
(Date:12/19/2014)... If you have ever been unable ... probably wished you had an arsenal of treatments to ... and other breathing disorders. Currently, the only proven methods ... but other common treatments do exist. At the ... Antonio, TX, 34 asthma educators responded to a Harmonica ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Consilium ... at the AMSUS Society for Federal Health Professionals ... locum tenens industry to military and federal healthcare ... the National Veterans Small Business Engagement (NVSBE) conference ... continues to be a vital solution in addressing ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
Breaking Medicine News(10 mins):Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3
... More than eight out of 10 homeless people surveyed ... least one chronic health condition and more than half have ... they live in unsafe, unstable or unaffordable housing--had equally poor, ... The underlying cause for these health issues is poverty, said ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... as nuts, to your diet can lower your cholesterol more ... Foods with plant sterols also have known cholesterol-reducing properties, and ... cholesterol by more than 13 percent. A low-fat diet alone ...
... , New York, NY, August 24, 2011 Nearly three-quarters (72%) ... their jobs over the last two years said that they ... because of cost, according to a new Commonwealth Fund ... or medical debt, compared to about half (49%) who lost ...
... Aug. 23 (HealthDay News) -- Accidental exposure to highly ... the United States, a new study finds. Researchers ... in outpatient chemotherapy infusion centers and found that nearly ... exposed to the drugs. In the United States, ...
... , TUESDAY, Aug. 23 (HealthDay News) -- ... appears to worsen over time and may lead to an ... people with diastolic dysfunction, which often comes with advancing age, ... abnormal way and is accompanied by elevated filling pressures. ...
... August 23, 2011 In a joint research effort ... with help from scientists at The University of Pennsylvania, ... Health, investigators from the Florida campus of The Scripps ... allows cells to rid themselves of damaged mitochondria, which ...
Cached Medicine News:Health News:Study: 85 percent of homeless people have chronic health conditions 2Health News:Certain Foods Said to Help Lower Bad Cholesterol 2Health News:Certain Foods Said to Help Lower Bad Cholesterol 3Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 2Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 3Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 4Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Scripps Research scientists define cellular pathway essential to removing damaged mitochondria 2
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...
... water content spherical soft lens manufactured using ... molding technology, and designed for use in ... a daily wear or extended wear basis. ... transmission, while an increased mid-peripheral thickness allows ...
Hertel exophthalmometer...
Medicine Products: